Revance Therapeutics (NASDAQ:RVNC) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report released on Saturday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on RVNC. HC Wainwright restated a “neutral” rating and issued a $6.60 price target on shares of Revance Therapeutics in a report on Friday, November 8th. Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Barclays reduced their price target on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a report on Monday, December 23rd. Finally, Mizuho reduced their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a report on Tuesday, December 10th. Nine analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, Revance Therapeutics presently has an average rating of “Hold” and a consensus target price of $8.39.

Revance Therapeutics Price Performance

RVNC opened at $3.65 on Friday. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.56. The company has a fifty day moving average of $3.41 and a 200-day moving average of $4.57. The stock has a market cap of $381.02 million, a PE ratio of -1.89 and a beta of 0.90.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. LMR Partners LLP bought a new position in shares of Revance Therapeutics in the third quarter valued at $11,648,000. Alpine Associates Management Inc. bought a new position in shares of Revance Therapeutics in the third quarter valued at $21,605,000. Oddo BHF Asset Management Sas bought a new position in shares of Revance Therapeutics in the third quarter valued at $3,763,000. FNY Investment Advisers LLC lifted its position in shares of Revance Therapeutics by 160.4% during the fourth quarter. FNY Investment Advisers LLC now owns 477,823 shares of the biopharmaceutical company’s stock valued at $1,452,000 after purchasing an additional 294,323 shares in the last quarter. Finally, Wellington Management Group LLP bought a new position in shares of Revance Therapeutics during the third quarter valued at about $2,315,000. 97.70% of the stock is owned by institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.